Nathalie Brandenberg is a pioneer in organoids research. Swiss born, she is a serial entrepreneur, innovator and scientist.

In 2014, she designed with Sylke Hoehnel-Ka the first technology enabling organoid culture at scale, commercialised as Grid3D by SUN Bioscience, the company they cofounded. In 2022, they established Doppl to propel organoid research for pharmaceutical, nutrition and clinical applications.

Nathalie is currently CSO at Doppl, executive board member at Doppl and Sun Bioscience and holds various advisory board positions in the healthcare sector in Switzerland.

Nathalie holds a MSc and a PhD in Bioengineering and Biotechnology from EPFL (2011, 2017) as well as an executive MBA from University of Lausanne (2022).

Nathalie was selected in the Forbes’ inaugural 30 Under 30 Europe list in the category Science and Health Care, was a finalist for the Swiss Economic Forum Woman Award in 2021 and she was awarded the EPPL alumni award in 2022, at solely 35 years old.